Also in Neuroblastoma patients, Forlenza et al. 28 evaluated whether combinations of KIR3DL1 and HLA ligands could influence patient outcome after treatment with anti-GD2 monoclonal antibody. Here, KIR3DL1 is linked to neuroblastoma.